Live Breaking News & Updates on Bioworld Medtech

Stay updated with breaking news from Bioworld medtech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lyra sinks as rhinosinusitis drug-device misses in phase III

Less than a week ago, executives at Lyra Therapeutics Inc. were looking ahead to “imminent” data from its first phase III study in chronic rhinosinusitis (CRS), testing drug-device candidate LYR-210, a drug-device candidate largely expected to fill a much-needed gap in CRS treatment. On Monday, May 6, they were announcing plans to preserve cash in the wake of the failed Enlighten 1 study, which raised doubts as to the feasibility of the company’s CRS programs, which also include the similarly designed candidate LYR-220. ....

Lyra Therapeutics Inc , Lyra Therapeutics , Lyr 220 , Lyra Therapeutics Inc , Bioworld Medtech , Combination Drug Device , Lyr 210 , Mometasone Furoate , Chronic Rhinosinusitis ,

Quest and Pathai sign multipart collaboration

Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The collaboration includes Quest’s acquisition of Pathai Diagnostics – the division that provides anatomic and digital pathology laboratory services – and licensing of Pathai’s Aisight digital pathology image management system. The companies also said they may work together on development of Pathai’s algorithm products and that Quest will be a preferred provider for Pathai’s biopharmaceutical clinical laboratory services. ....

Pathai Aisight , Quest Diagnostics Inc , Pathai Inc , Quest Diagnostics , Pathai Diagnostics , Bioworld Medtech , Pathai Inc , Quest Diagnostics Inc , Deals Andm Amp A ,

FDA wary of impact of retirements on inspectional activities

The U.S. FDA’s senior managers often lament the lack of routine increases in taxpayer funding, a concern that Michael Rogers, the associate FDA commissioner for regulatory affairs, reiterated during a May 1 webinar. Rogers said the agency’s field inspectorate will be working through a large number of retirements over the next few years, a predicament he said will continue to be “a huge challenge” to overcome. ....

Michael Rogers , Bioworld Medtech , Fda Office Of Regulatory Affairs , Fda Ora , Fda Oii , Alliance Fora Stronger Fda ,

FDA's final LDT rule prompts more calls for passage of VALID Act

The U.S. FDA has posted the long-awaited final rule for lab-developed tests, which amends the draft rule in a few key respects, but Reps. Diana DeGette and Larry Buchson, once again voiced their opposition to the rule. DeGette and Bucshon acknowledged that congressional inaction has left the FDA with few choices, but called again for passage of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act, which they said is critical because “burdensome regulation of these medical products creates uncertainty in the future of innovation and patient care.” ....

Larry Buchson , Diana Degette , Verifying Accurate , Bioworld Medtech , Valid Act , Lab Developed Tests , Final Rule ,

Front Line granted CE mark for smallest aortic occlusion device

Front Line Medical Technologies Inc. recently received CE mark for its Cobra-OS, the smallest REBOA (resuscitative endovascular balloon occlusion of the aorta) device for use in emergency situations on the market. The company believes that Cobra-OS could help save the lives of patients during traumatic bleeding situations as it could buy valuable time until definitive care can be provided. ....

Front Line Medical Technologies Inc , Front Line Medical Technologies , Bioworld Medtech , Cobra Os , Front Line Medical Technologies Inc , Face Mark , Emergency Department ,